Spruce Biosciences Inc. (SPRB)
SPRB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/0001193125-26-097558-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SPRB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001683553 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$39.0M |
| Operating income | -$36.5M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $48.9M |
| Total assets | $53.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements." | 10-Q 2026-11-09 |
| Cash and burn | $87.7M cash; operating cash flow -$12.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,874,013 (2026-11-05); 1,070,370 a year earlier; 40,710,692 three years earlier. 3y figure adjusted for splits (1-for-5625 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 2; latest 1-for-75 on 2025-08-07 | Source 2025-08-07 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-04-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Jose, California, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5K, sold $5K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$24.0M | -$13.8M | $87.7M | $19.5M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$16.2M | -$22.1M | $96.3M | $19.9M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$12.3M | -$8.7M | $54.1M | $20.4M | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $0 | -$14.6M | -$6.5M | $48.9M | $0 | $0 | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $0 | -$8.2M | -$5.3M | $10.7M | $549K | $697K | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | $0 | -$2.1M | -$8.8M | $16.4M | $972K | $1.3M | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | $0 | -$14.0M | -$12.7M | $25.6M | $1.4M | $2.9M | 10-Q 2025-05-06 |
| Q4 2024 2024-12-31 | $697K | -$23.6M | -$20.7M | $38.8M | $1.8M | $4.9M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-21 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 369 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.0% |
| 1 month | +7.3% |
| 3 months | -13.0% |
| Year to date | -50.3% |
| 1 year | -61.5% |
| From 52-week high | -62.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics Inc. | $0.4486 | -5.40% | $124.6M |
| ALXO | ALX Oncology Holdings Inc. | $1.00 | -3.85% | $124.9M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier